2024
Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins
Vijayaraghavan K, Baum S, Desai N, Voyce S. Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins. Frontiers In Cardiovascular Medicine 2024, 10: 1308173. PMID: 38288054, PMCID: PMC10822878, DOI: 10.3389/fcvm.2023.1308173.Peer-Reviewed Original ResearchLDL-CCV riskPeripheral arterial diseaseArtery diseaseCumulative incidence of CV eventsCV diseaseLowering of low-density lipoprotein cholesterolPatients treated with statinsIncidence of CV eventsLong-term event ratesWell-controlled LDL-CLow-density lipoprotein cholesterolLDL-C reductionAdd-on agentEvent ratesFirst-line treatmentResidual cardiovascular riskCV event ratesCoronary artery diseaseCV-related deathOmega-3 fatty acids eicosapentaenoic acidFirst-lineCumulative incidenceEicosapentaenoic acidCV events
2022
COST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS
Campbell C, Desai N, Electricwala B, Constanti M, Trueman D, Woodcock F, Cristino J. COST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS. Journal Of The American College Of Cardiology 2022, 79: 1559. DOI: 10.1016/s0735-1097(22)02550-5.Peer-Reviewed Original ResearchElevated low-density lipoprotein cholesterolLow-density lipoprotein cholesterolStatin useLipoprotein cholesterolInclisiranPatientsAtheroscleroticThreshold analysisCholesterol
2021
PCSK9 Inhibiting Monoclonal Antibodies
Ahmed Z, Juthani P, Lee M, Desai N. PCSK9 Inhibiting Monoclonal Antibodies. Stroke Revisited 2021, 125-133. DOI: 10.1007/978-981-16-3923-4_11.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Lipid-lowering medicationsSubset of patientsIschemic strokeLower PCSK9Low-density lipoprotein cholesterolConvertase subtilisin/kexin type 9Subtilisin/kexin type 9Monoclonal antibodiesCoenzyme A (HMG-CoA) reductase inhibitorsComponents of dyslipidemiaHigh-intensity statinsStroke risk reductionModifiable risk factorsHealthy lifestyle modificationsLDL-C levelsRisk of strokeStatin-induced myopathyTreatment of hyperlipidemiaA Reductase InhibitorsLifestyle modificationStatin useLipoprotein cholesterolPCSK9 inhibitorsStroke outcome
2015
National assessment of statin therapy for patients with acute myocardial infarction, 2001–11: insight from the China PEACE-Retrospective Acute Myocardial Infarction study
Zhang L, Li J, Li X, Nasir K, Zhang H, Wu Y, Hu S, Wang Q, Downing N, Desai N, Masoudi F, Spertus J, Krumholz H, Jiang L, Group O. National assessment of statin therapy for patients with acute myocardial infarction, 2001–11: insight from the China PEACE-Retrospective Acute Myocardial Infarction study. The Lancet 2015, 386: s42. DOI: 10.1016/s0140-6736(15)00623-6.Peer-Reviewed Original ResearchIntensive statin therapyAcute myocardial infarctionAcute Myocardial Infarction StudyStatin therapyMyocardial Infarction StudyMyocardial infarctionStatin useCardiovascular diseaseLow-density lipoprotein cholesterolStatin therapy useLong-term mortalityUse of statinsNumber of patientsTwo-stage random sampling designMultilevel logistic regression modelsCochran-Armitage testLogistic regression modelsWestern rural regionStatin regimensEligible patientsHospital mortalityLipoprotein cholesterolFamily Planning CommissionIntensive therapyTherapy use